changes in protein profiles in bortezomib applied multiple myeloma ...
changes in protein profiles in bortezomib applied multiple myeloma ...
changes in protein profiles in bortezomib applied multiple myeloma ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
expressed primarily <strong>in</strong> hematopoietic organs especially bone marrow. After the<br />
Bortezomib, the afore-mentioned prote<strong>in</strong> came to light to carry out its function. The<br />
other prote<strong>in</strong> was Mothers aga<strong>in</strong>st decapentaplegic homolog 7 that is <strong>in</strong>volved <strong>in</strong> cell<br />
signal<strong>in</strong>g.<br />
Spot 8, Suppressor of tumorigenicity 7 prote<strong>in</strong> may act as a tumor suppressor. It<br />
is another newly formed prote<strong>in</strong>.<br />
Spot 27, Apoptosis Regulatory Prote<strong>in</strong> Siva <strong>in</strong>duces CD27-mediated apoptosis<br />
and <strong>in</strong>hibits BCL2L1 isoform Bcl-x(L) anti-apoptotic activity. It is also <strong>in</strong>hibits<br />
activation of NF-κB and promotes T-cell receptor-mediated apoptosis. So, generation of<br />
this prote<strong>in</strong> after the Bortezomib stress is vital for cancerous cells.<br />
Spot 35 has three opportunities s<strong>in</strong>ce it did not determ<strong>in</strong>e exactly. One of them<br />
was Ras-related prote<strong>in</strong> Rab-43. The others were Interleuk<strong>in</strong>-32 and Myos<strong>in</strong> light<br />
polypeptide 6. IL-32 is a cytok<strong>in</strong>e that may play a role <strong>in</strong> <strong>in</strong>nate and adaptive immune<br />
responses. It <strong>in</strong>duces various cytok<strong>in</strong>es such as TNFA/TNF-alpha and IL8 and activates<br />
typical cytok<strong>in</strong>e signal pathways of NF-κB and p38 MAPK.<br />
Spot 9 has two alternatives: Bone marrow stromal antigen 2 and NF-κB p105<br />
subunit. First prote<strong>in</strong> may be <strong>in</strong>volved <strong>in</strong> the sort<strong>in</strong>g of secreted prote<strong>in</strong>s and pre-B-cell<br />
growth. Also it may play a role <strong>in</strong> B-cell activation. NF-κB is a pleiotropic transcription<br />
factor which is present <strong>in</strong> almost all cell types and is <strong>in</strong>volved <strong>in</strong> many biological<br />
processed such as <strong>in</strong>flammation, immunity, differentiation, cell growth, tumorigenesis<br />
and apoptosis. NF-κB is a homo- or heterodimeric complex formed by the Rel-like<br />
doma<strong>in</strong>-conta<strong>in</strong><strong>in</strong>g prote<strong>in</strong>s RELA/p65, RELB, NFKB1/p105, NF-κB1/p50, REL and<br />
NF-κB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one.<br />
The dimers b<strong>in</strong>d at κB sites <strong>in</strong> the DNA of their target genes and the <strong>in</strong>dividual dimers<br />
have dist<strong>in</strong>ct preferences for different κB sites that they can b<strong>in</strong>d with dist<strong>in</strong>guishable<br />
aff<strong>in</strong>ity and specificity. Different dimer comb<strong>in</strong>ations act as transcriptional activators or<br />
repressors, respectively. NF-κB is controlled by various mechanisms of post-<br />
translational modification and subcellular compartmentalization as well as by<br />
<strong>in</strong>teractions with other cofactors or corepressors. NF-κB complexes are held <strong>in</strong> the<br />
cytoplasm <strong>in</strong> an <strong>in</strong>active state complexed with members of the NF-κB <strong>in</strong>hibitor (IκB)<br />
family. In a conventional activation pathway, IκB is phosphorylated by IκB k<strong>in</strong>ases<br />
(IKKs) <strong>in</strong> response to different activators, subsequently degraded thus liberat<strong>in</strong>g the<br />
active NF-κB complex which translocates to the nucleus. NF-κB heterodimeric p65-p50<br />
and RelB-p50 complexes are transcriptional activators. The NF-κB p50-p50 homodimer<br />
85